US FDA approves GSK's prostate combination pill
This article was originally published in Scrip
Executive Summary
The US FDA has approved GlaxoSmithKline's single capsule combination of Avodart (dutasteride 0.5mg) and tamsulosin 0.4mg for the treatment of symptomatic benign prostatic hyperplasia (BPH).